Why anti-Bcl-2 clinical trials fail: a solution

@article{Harazono2013WhyAC,
  title={Why anti-Bcl-2 clinical trials fail: a solution},
  author={Yosuke Harazono and Kosei Nakajima and Avraham Raz},
  journal={Cancer and Metastasis Reviews},
  year={2013},
  volume={33},
  pages={285-294}
}
The alteration in expression of B cell lymphoma-2 (Bcl-2) family of protein members in cancer is involved mainly in the regulation of apoptosis. Bcl-2 family proteins are currently used as major targets in the development of methods to improve treatment outcomes for cancer patients that underwent clinical trials. Although many agents have been developed for targeting Bcl-2 in the past decade, some previous attempts to target Bcl-2 have not resulted in beneficial clinical outcome for reasons… CONTINUE READING
Highly Cited
This paper has 30 citations. REVIEW CITATIONS

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

A case of intravascular large B cell lymphoma: New clinical and immunohistochemical findings.

Neuropathology : official journal of the Japanese Society of Neuropathology • 2016
View 7 Excerpts
Highly Influenced

Galectin Targeted Therapy in Oncology: Current Knowledge and Perspectives

International journal of molecular sciences • 2018
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 104 references

Drugs targeting Bcl-2 family members as an emerging strategy in cancer.

Expert reviews in molecular medicine • 2010
View 13 Excerpts
Highly Influenced

Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2008
View 5 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…